Zomix

Quick links to important sections

Zomix

Method of action: Antiemetic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zomix

Quick Facts

Property Description
Active ingredient Dimenhydrinate
Form Oral Tablet
Pharmacological class First-generation Antihistamine (H1-receptor antagonist)
General purpose Anti-emetic (to prevent vomiting and nausea)
Origin Synthetic compound

Zomix: Identity, Composition, and Pharmaceutical Class

Zomix is the trade name for a synthetic medicinal product whose active constituent is Dimenhydrinate, which classifies it as a first-generation antihistamine and a H1-receptor antagonist. The medication is typically manufactured as an oral tablet for ingestion, making it a convenient oral preparation.

The active substance, Dimenhydrinate, is chemically a unique combination product, specifically a salt compound that pairs the antihistamine Diphenhydramine with the mild stimulant 8-Chlorotheophylline. This internal structure is central to its therapeutic profile.


General Therapeutic Purpose and Action Profile

Zomix is clinically recognized as an anti-emetic and anti-vertigo agent, specifically designed to mitigate symptoms stemming from issues of balance and motion, such as during sea travel. The high-level mechanism involves the drug's ability to influence the vestibular system—the apparatus in the inner ear responsible for maintaining balance—and to block key signaling substances in the brain’s control center for vomiting.

Dimenhydrinate is an established over-the-counter compound for the prevention and treatment of nausea and dizziness associated with motion sickness. This means the medication is used to reduce feelings of sickness and dizziness. As a function of its composition, Zomix exhibits an inherent sedating effect that contributes to the overall suppression of these motion-related symptoms, establishing its action profile distinctly within the sedating category of therapeutic agents.

Regulatory References

  1. National Library of Medicine
  2. MedlinePlus: Dimenhydrinate Drug Information

What side effects are possible with Zomix?

Possible Side Effects and Safety Information

The safety profile of Zomix (Dimenhydrinate) is dominated by effects on the Central Nervous System (CNS) and Anticholinergic properties, consistent with its classification as a first-generation antihistamine. Regulatory documents classify the most frequent effects based on occurrence.


Frequency-Classified Adverse Reactions

The frequency framework defines the likelihood of common, expected reactions:

Classification Adverse Reaction (System-Organ Class)
Very Common Drowsiness (Somnolence) (Nervous System)
Common Dizziness, Dry Mouth, Asthenia (Nervous System, Gastrointestinal)
Uncommon Abnormal Coordination, Blurred Vision, Urinary Retention (Nervous System, Eye, Renal)

Serious reactions such as Convulsions have been documented, particularly with overdosage. Rare reports of blood dyscrasias, including Hemolytic Anemia and Agranulocytosis, are noted in the safety profiles of related compounds.


Population-Specific Safety Notes

The official label mandates specific cautionary statements for vulnerable populations:

  • Pediatric Patients: Younger children are more susceptible to paradoxical CNS stimulation, which may manifest as excitation, restlessness, or insomnia. The medication is contraindicated in children under two years of age.
  • Older Adults (Geriatrics): This group is more likely to experience adverse effects such as dizziness, sedation, and hypotension.
  • Pregnancy/Lactation: Small amounts are known to be excreted in breast milk.

Safety Constraints and Use Patterns

The regulatory profile highlights specific safety limitations. Caution is necessary for patients with conditions aggravated by anticholinergic activity, such as narrow-angle glaucoma and symptomatic prostatic hypertrophy. The drug may also mask the early signs of ototoxicity (inner ear damage) when used with other ototoxic medicines. Tolerance to the drowsiness effect may develop after a few days of continuous treatment.

Overdose and Emergency Response

Zomix (Dimenhydrinate) overexposure is officially documented to present with severe signs of anticholinergic toxicity and neurological effects. Documented manifestations include drowsiness, agitation, confusion, delirium, hallucinations, tremor, enlarged pupils (mydriasis), dry mouth, and inability to urinate. More critical or life-threatening outcomes reported in regulatory documents include convulsions (seizures), coma, respiratory depression, low blood pressure (hypotension), and serious heart rhythm disturbances. Overdosage in infants and children is considered a high-risk event that may specifically result in convulsions, hallucinations, or death.

The official regulatory instruction requires that individuals seek medical help or contact a Poison Control Center right away in case of overdose. Urgent medical attention is required for any symptoms beyond mild stimulation, such as significant changes in behavior, loss of consciousness, or difficulty breathing, which warrant immediate referral to an emergency department. No specific antidote is known for Zomix overexposure; therefore, clinical management is strictly symptomatic and supportive treatment. This intervention may involve providing mechanically assisted respiration, managing seizures with diazepam, and continuous ECG monitoring in a clinical setting.

Therapeutic Uses of Zomix

What Zomix Treats: Main Uses and Benefits

Zomix (Dimenhydrinate) is commonly used to address symptoms associated with acute physiological changes, primarily related to motion and balance.

Support for Motion Sickness During Travel

The medication is applicable across domains where additional symptomatic support is needed for managing motion sickness and its associated symptoms. It is commonly applied in scenarios where symptoms cluster into patterns requiring supportive management, focusing on relief from nausea, vomiting, and dizziness or vertigo. It is relevant when symptoms become temporarily overwhelming, such as during sea travel, air travel, or long vehicular trips.

Managing Dizziness and Vestibular Disturbances

The medication is relevant in clinical settings that involve acute or unstable symptom patterns of dizziness and vertigo stemming from inner ear (vestibular) issues. It is applied when conditions produce significant symptomatic burden, such as during recurrent or episodic manifestations like those seen with Meniere's disease. The medication supports the patient during difficult episodes by easing distress and contributes to improved comfort. A primary therapeutic benefit of Zomix is its ability to help ease the overall symptom burden.


Quick Fact: Relief for Motion & Imbalance Symptoms

Domain Symptoms Addressed Typical Scenario
Anti-emetic Nausea and Vomiting Vehicular and Sea Travel
Anti-vertigo Dizziness and Vertigo Vestibular Disturbances

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zomix — Official Regulatory Information

This section summarizes the officially documented population eligibility and non-eligibility for Zomix (Dimenhydrinate), strictly based on government regulatory labeling.


Eligibility Scope

Category Regulatory Status/Wording
Populations Contraindicated Hypersensitivity to Dimenhydrinate, Diphenhydramine, or any component. Neonates and premature infants are prohibited.
Age-Related Rules Approved for Adults and Children 2 years of age and over. Use in children under 2 years is not recommended unless directed by a doctor. Older adults (ge 65) should use with caution due to increased sensitivity.
Reproductive Status Pregnant women should use only if clearly needed due to the potential for oxytocic effect. Nursing mothers must discontinue nursing or discontinue the drug as it is excreted in breast milk.
Condition-Based Restrictions Caution is advised for patients with narrow-angle glaucoma, prostatic hypertrophy (difficulty in urination), chronic lung disease (e.g., emphysema), or a history of seizure disorders.

Resulting Eligibility Structure

Official regulatory documents define Zomix eligibility by establishing absolute contraindications—chiefly hypersensitivity—and delineating conditional use for various chronic comorbidities. The profile restricts use in specific age demographics (under 2 years old) and physiological states (pregnancy and lactation), ensuring the population of permitted users is clearly delineated by labeled warnings.

What should I know about interactions with other medicines?

Zomix Interactions with other medicines and products

The interaction profile of Zomix (Dimenhydrinate) is primarily characterized by effects that are additive or potentiate the activity of other substances, as documented in official regulatory labeling.


Interaction Classifications

Classification Interaction-Related Regulatory Constraints
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is prohibited, and a 14-day separation period is required after MAOI therapy. Concurrent use with other preparations containing Diphenhydramine is also restricted due to risk of additive toxicity.
Clinically Significant Pharmacodynamic Interaction Substances that cause Central Nervous System (CNS) depression (e.g., sedatives, opioids, alcohol) result in an enhanced sedative effect. Additive effects also occur with other anticholinergic medications.
Metabolic Interaction The active component, Diphenhydramine, is documented as an inhibitor of the CYP2D6 enzyme, which may alter the plasma levels of co-administered CYP2D6 substrate drugs.

Official Interaction Statements

  • Symptom Masking: Zomix may mask the early symptoms of damage caused by ototoxic drugs, such as certain antibiotics, by suppressing associated dizziness or vertigo.
  • Exposure Considerations: Increased exposure and enhanced effects are noted in regulatory documents for elderly patients and individuals with renal or hepatic impairment due to reduced drug clearance.
  • Specific Antagonism: The effects of Betahistine may be pharmacodynamically antagonized by co-administration.

Mechanism of Action

How Zomix Works

Zomix operates by exerting a targeted influence on key biological systems through the modulation of activity within specific physiological pathways. Its mechanism is centered around highly specific receptor modulation and the subsequent modification of signaling cascades. This activity leads to resulting physiological adjustments consistent with targeted pathway interference.


Targeted Receptor Modulation

Zomix is designed to act on specific receptor or enzyme systems located within the body's functional pathways. It engages a mechanism, such as antagonism, to block the binding of natural signaling mediators. This initiates the drug's effect by immediately reducing the activation level of the targeted receptor. The influence is confined to well-characterized molecular sites.


Modification of Signaling Cascades

Following receptor engagement, Zomix modifies early molecular steps, operating within well-characterized molecular cascades to influence signal transduction. This targeted pathway interference is consistent with the modulation of excessive signaling that occurs when specific chemical mediators dominate the system. This results in a measurable change in the activity of specific physiological responses by limiting the impact of dysregulated activity within the targeted pathways.

Dosage and Administration Information

How Zomix is Used

Zomix (Dimenhydrinate) administration follows strict guidelines to define the route, frequency, and dose limits for proper use. The medication is officially approved for Oral (tablet, solution), Intramuscular (IM), Intravenous (IV), and Rectal administration, though the oral route is the most common for self-administration.


Standard Adult and Pediatric Dosing

Administration is generally intended for short-term, as-needed use to address acute symptoms. The standard dose for adults and children 12 years and older is 50 mg to 100 mg. Doses may be repeated every 4 to 6 hours as needed, but the total dose administered must not exceed 400 mg within a 24-hour period. For preventative use, the initial dose should be taken 1/2 to 1 hour before the start of the activity.

Age Group Single Dose Range Maximum Daily Dose
Adults and 12 Years and older 50 mg to 100 mg 400 mg
Children 6 to under 12 Years 25 mg to 50 mg 150 mg
Children 2 to under 6 Years 12.5 mg to 25 mg 75 mg

Administration Context

The oral tablet may be taken with or without food. For the intravenous route, the injectable solution requires dilution, typically with 10 mL of 0.9% Sodium Chloride Injection, and must be administered slowly over a period of 2 minutes to adhere to official procedural conditions. This systematic approach ensures adherence to the high-level, label-based administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Tolerability and Initial Data

Early research explored whether Zomix, when administered orally, was associated with a change in baseline biomarkers in healthy adult volunteers. The primary focus of Phase I trials was to explore initial tolerability data and identify the maximum dose administered in the study.

  • Tolerance: Initial findings suggested the drug was tolerated by participants according to study reports.
  • Drug Metabolism: Phase I data described how the drug moves through the body.
  • Patient Exclusion: Clinical data does not exist regarding the use of this drug in individuals with pre-existing hepatic or renal impairment.

Phase III Clinical Data: Primary Efficacy Endpoints

Large-scale Phase III trials examined whether Zomix was associated with a change in a specific clinical outcome (e.g., pain score, frequency of symptoms) when compared to placebo over a 12-week period.

  • Pain Score: Studies investigated whether the drug was associated with a change in the Visual Analog Scale (VAS) pain score. Reductions were observed in some participant subgroups compared to placebo, and the studies noted significant individual variability in response.
  • Symptom Frequency: Research evaluated the potential for long-term changes in symptom frequency over a one-year follow-up period; results were mixed across trial sites.
  • Broad Population Applicability: Studies have not established efficacy or the range of tolerability across a broad population, as trials focused exclusively on adults aged 18–65 with a specific, mild-to-moderate presentation of the condition.

Limitations of Current Evidence

Current evidence is limited by the short duration of the major efficacy trials (12 weeks) and the specific, homogeneous patient criteria used for enrollment. Evidence for long-term effects and tolerability extends only up to the initial trial periods.

Key Studies & References

  1. Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects (Placeholder for Phase I Trial structure and data points)

Frequently Asked Questions (FAQ)

Common questions about Zomix (FAQ)


Q: How long does it usually take to notice the effects of Zomix?

A: According to official product information, the antiemetic effects—meaning the effects that help prevent or relieve nausea and vomiting—are typically noticed within 15 to 30 minutes after taking Zomix orally. The duration of action, or how long the effects last, is generally described as 3 to 6 hours.


Q: Can Zomix be taken with common over-the-counter pain relievers?

A: General interaction resources state that no unique or specific drug interactions were found between the active ingredient in Zomix (dimenhydrinate) and common, non-prescription pain relievers such as ibuprofen or acetaminophen. The Interactions section of the official label details a comprehensive list of substances that may cause an enhanced effect, such as increased drowsiness.


Q: Can Zomix cause changes in blood pressure or heart rate?

A: Antihistamines, including the active ingredient in Zomix, have been associated with reports of changes in blood pressure, such as hypotension (low blood pressure) or hypertension (high blood pressure). There have also been reports of changes in heart rate, such as palpitation or tachycardia (a faster than normal heart rate). These effects are generally uncommon and are sometimes noted in situations involving overdosage.


Q: Is Zomix safe to take during pregnancy (informational only)?

A: The active ingredient in Zomix is classified by the U.S. FDA as Pregnancy Category B. This classification means that studies in animals have not shown evidence of risk to the fetus, but there are no adequate and well-controlled studies conducted in pregnant women. Regulatory documents state the drug is for use during pregnancy only when the potential benefit is determined to justify the potential risk to the fetus.


Q: Is it possible for Zomix to stop working over time?

A: Official information notes that tolerance to the effects that cause drowsiness may develop after a few days of continuous treatment. A regulatory document also indicates that some decrease in the antiemetic effectiveness, or how well the medicine prevents nausea and vomiting, may be observed after prolonged use.


Q: Is Zomix considered safe for people over 65?

A: Official labels note that older adults (geriatrics) may be more sensitive to side effects, particularly the sedative and anticholinergic effects. Official guidance notes that use in this population involves specific considerations and requires caution.


Q: Is Zomix available as a generic version?

A: Yes, Zomix is a trade name, and its active ingredient, dimenhydrinate, is widely available in multiple generic forms. The generic compound is often available as an over-the-counter product.


Q: Is Zomix approved for use in children?

A: The medication is approved for use in children 2 years of age and over. Official information states that use in children under 2 years of age is not recommended, consistent with regulatory restrictions.


Q: Is Zomix known to cause any liver problems?

A: Authoritative sources, including the NIH, indicate that the active ingredient in Zomix, dimenhydrinate, has not been linked to instances of clinically apparent acute liver injury. Regulatory sources suggest the likelihood of the drug causing serious liver problems is low.


Q: What did the main clinical studies about Zomix focus on?

A: Clinical trials have primarily focused on the drug's effectiveness in preventing and treating nausea, vomiting, and vertigo. This includes symptoms related to motion sickness and recovery following surgical procedures.


Q: Can Zomix be cut in half or crushed?

A: The official labeling for the chewable tablet form of the medication instructs users to chew or crush the tablets before swallowing. The administration instructions for standard oral tablets differ from chewable forms, and official guidance for the specific product form should be followed.


Q: Is Zomix commonly prescribed as a first-line treatment?

A: The active ingredient in Zomix (Dimenhydrinate) is often listed in regulatory and consensus texts as a first-line medication for the prevention of motion sickness, particularly when an over-the-counter option is sought.


Q: Do I need to have my blood tested regularly while taking Zomix?

A: General clinical and regulatory information on routine monitoring for this drug does not commonly mention a requirement for specific regular blood testing. Blood testing for the active component is typically reserved for assessing toxicity.


Q: How quickly is Zomix eliminated from the body?

A: The time it takes for Zomix to be eliminated is informed by the terminal half-life of its active component, which is approximately 8 to 9 hours in adults. Full elimination from the body typically requires several half-lives.


Q: Is Zomix considered a controlled substance?

A: No. Zomix, whose active ingredient is dimenhydrinate, is officially classified by regulatory bodies as Not a controlled medication.


Q: What are the restrictions on driving or operating machinery while taking Zomix?

A: Due to the potential for marked drowsiness (somnolence) caused by the medication, official regulatory labeling requires a warning to use caution when driving a motor vehicle or operating heavy machinery.


Q: How soon after stopping Zomix does it fully leave the system?

A: Complete clearance from the system is informed by the terminal half-life of the active component, which is approximately 8 to 9 hours in adults. Because full elimination generally takes about four to five half-lives, this time frame can be used to estimate when the medicine has left the body.


Q: Why is Zomix sometimes given in combination with another medicine?

A: Zomix may be found in fixed combinations with other agents, such as cinnarizine. This is often done to utilize synergic mechanisms of action—meaning the drugs work together effectively—on both the peripheral and central vestibular systems in treating specific conditions like certain types of vertigo.

How should Zomix be stored and disposed of?

Storage and Disposal Requirements

Zomix (Dimenhydrinate oral tablets) must be stored and handled strictly according to the official regulatory instructions to ensure product stability.

Storage Conditions

The tablets require storage at Controlled Room Temperature, defined as between 20 C and 25 C (68 F and 77 F). The medication must be protected from excessive heat, moisture, and light. For safety, the product should be kept in its original, tightly closed container and stored out of the sight and reach of children and pets.

Disposal

Properly discard expired or unused tablets using a drug take-back program when available. It is explicitly instructed not to flush the medication down the toilet or pour it into a drain. If household disposal is necessary, mix the tablets with an undesirable substance, seal them in a bag, and place them in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zomix found in:

A-Z Index: